Cargando…
Effect of the Timing of Amubarvimab/Romlusevimab (BRII-196/198) Administration on Progression to Severe Disease in Elderly Patients with COVID-19 Infection: A Retrospective Cohort Study
OBJECTIVE: Early intervention with neutralizing antibodies is considered to be effective in preventing disease progression in patients with mild to moderate COVID-19 infection. Elderly patients are the most susceptible and at a higher risk of COVID-19 infection. The present study aimed to assess the...
Autores principales: | Xu, Yonghao, Liu, Ying, Zheng, Ruiqiang, Si, Shujie, Xi, Yin, Deng, Xilong, Wang, Gang, Zhou, Liang, Li, Manshu, Wang, Ya, Zhang, Shuo, Xie, Jianfeng, Liu, Xiaoqing, Yang, Yi, Tang, Xiaoping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240101/ https://www.ncbi.nlm.nih.gov/pubmed/37360309 http://dx.doi.org/10.1007/s44231-023-00040-9 |
Ejemplares similares
-
Amubarvimab/Romlusevimab: First Approval
por: Hoy, Sheridan M.
Publicado: (2022) -
Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
por: Ji, Yun, et al.
Publicado: (2022) -
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
Publicado: (2022) -
LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
por: Evering, Teresa H, et al.
Publicado: (2021) -
520. Pharmacokinetic and Safety Phase 1 Study and Microneutralization Assay Results with BRII-196/BRII-198, a Novel Antibody Cocktail Active Against a Wide Range of SARS-CoV-2 Variants
por: Margolis, David A, et al.
Publicado: (2021)